OTC drug review
Executive Summary
FDA announced in the April 29 Federal Register that three final monographs were projected for publication in April 1985: alertness aid, anthelmintic and otic drug products. Eight tentative final monographs were also projected for publication during the month (anorectal, fever blister, topical hormone, internal analgesic, internal deodorant, male genital desensitizer, smoking deterrent, and weight control products). However, the agency had previously projected October 1984 publication dates for five of these monographs (alertness aid, anorectal, anthelmintic, topical hormone, and internal analgesic drug products).
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.